Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer – Medscape
- Durvalumab Plus FLOT Ups Survival in Early Upper-GI Cancer Medscape
- AstraZeneca – IMFINZI-Based Regimen Reduced The Risk Of Death By 22% In Early Gastric Cancer Versus. Chemotherapy Alone In MATTERHORN Phase III Trial TradingView
- MATTERHORN Trial at ESMO 2025: Durvalumab Plus FLOT in Resectable Gastric and GEJ Adenocarcinoma Oncodaily
- Imfinzi Plus Chemo Improves Survival in G/GEJ Adenocarcinoma CUREtoday.com
- Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer Pharmacy Times